Introduction
Brain tumors represent the second most common cancer and the most common solid tumor in childhood, accounting for 4.3 cases per 100 000 person-years in the United States. 1 The incidence peaks among children from ages 3 to 7 years, although all ages are affected. In adults and older children, most tumors are located supratentorially; in young children, tumors of the central nervous system are more commonly infratentorial.
The improved outcome for children with medulloblastoma represents a success story for pediatric neurooncology. Five decades ago, children diagnosed with medulloblastoma faced almost certain death. Today, treatment that includes surgical resection, craniospinal irradiation, and chemotherapy cures approximately 80% to 85% of children diagnosed with average-risk medulloblastoma 2,3 and up to 70% of those classified with high-risk disease. 2 However, these remarkable improvements in survival are achieved at a high cost to quality of life. Many survivors experience significant long-term neurocognitive [4] [5] [6] and neuroendocrine effects. 7 Intriguingly, these advances in outcome have been achieved through the systematic use of empirically based treatment regimens, including craniospinal irradiation and chemotherapy, not through increased understanding of tumor biology and novel therapies.
In stark contrast, little progress in survival has been made for children with high-grade gliomas. In spite of modern aggressive multimodality therapy, including surgery, radiotherapy, and chemotherapy, survival remains very poor, with 2-year progression-free survival less than 20%. 8 The role of maximum safe surgical resection and radiotherapy are well established in the treatment of pediatric highgrade glioma. On the other hand, the role of chemotherapy in the treatment of these tumors remains undefined.
Very young children (generally defined as those less than 3 years) with brain tumors continue to pose a unique therapeutic challenge. Craniospinal irradiation is typically not administered to them because of the devastating neurocognitive sequelae associated with its use. [4] [5] [6] This limitation in therapy and the distinct biological characteristics of these tumors are likely reasons that children less than 3 years old with embryonal tumors generally have a poor prognosis despite very aggressive treatment. 9, 10 However, for selected subgroups of patients, most notably those with localized, completely resected medulloblastoma, survival has improved. In this article, we review the role chemotherapy has played in the treatment of medulloblastoma and high-grade gliomas.
Older Children With Medulloblastoma
The cure rates for children and young adults diagnosed with medulloblastoma have improved significantly in the (Table 1) . 11 Improved ability to perform gross total resections, introduction of magnetic resonance imaging (MRI) to accurately stage patients, advanced techniques to deliver radiation therapy, and improved supportive care have all contributed to this success, but the introduction of chemotherapy has played a key role.
The first randomized study that suggested the efficacy of chemotherapy in medulloblastoma treated all patients with craniospinal irradiation (36 Gy), with a boost to posterior fossa of 54 Gy and weekly vincristine during radiation therapy. The patients were subsequently randomly assigned to receive either no adjuvant chemotherapy or 8 cycles of lomustine, prednisone, and vincristine. Among the patients treated with adjuvant therapy, those with more advanced disease had a survival advantage compared with those on the nonchemotherapy arm. 17 The first International Society of Pediatric Oncology (SIOP) trial with a similar study design demonstrated similar results. 18 Because of the deleterious neurocognitive and neuroendocrine consequences associated with this treatment, the next generation of cooperative group studies tested the efficacy of reduced craniospinal irradiation dose for patients with average-risk disease. Patients with gross total resections and no metastatic disease (M0R0) were categorized as having average-risk disease.
In a randomized study for average-risk medulloblastoma patients that compared standard-dose radiotherapy (36 Gy to the craniospinal axis and 54 Gy to the posterior fossa) with reduced-dose radiotherapy (23.4 Gy to the craniospinal axis and 54 Gy to the posterior fossa), the mean probability of event-free survival at 5 years was 67% + 7.4% and 52% + 7.7%, respectively (P ¼ .080). 19, 20 A subsequent pilot study used reduced-dose craniospinal irradiation (23.4 Gy) with concurrent weekly vincristine during radiotherapy and 8 cycles of adjuvant chemotherapy consisting of lomustine, cisplatin, and vincristine that were administered after the completion of radiotherapy. Sixty-five children between the ages of 3 and 10 years with average-risk medulloblastoma were enrolled in the study. The probability of progression-free survival was 86% + 4% at 3 years and 79% + 7% at 5 years. 12 These study results suggest that a combination of reduced-dose craniospinal irradiation and effective chemotherapy are comparable to the results achieved using standard-dose craniospinal irradiation alone (5-year event-free survival probability, 67% + 7.4%).
Companion data from the earlier randomized trial conducted by the Pediatric Oncology Group (POG) and the Children's Cancer Group (CCG) suggested a difference in neurocognitive levels measured more than 3 years after irradiation. The decline in intelligence quotient (IQ) scores was most significant in children younger than 8.5 years, and the full-scale IQ scores of patients after treatment with 36 Gy craniospinal irradiation (70) were lower than those of patients after treatment with 23.4 Gy (85). 21 Together, the greater toxicity associated with higher dose craniospinal irradiation and the equivalent disease control achieved using adjuvant chemotherapy and reduced-dose craniospinal irradiation support the use of reduced-dose craniospinal irradiation together with chemotherapy as the new ''standard'' for therapy in children with medulloblastoma. This approach is now widely accepted as standard in North America.
In the recently concluded POG-CCG trial for averagerisk medulloblastoma (A9961), all patients were treated with craniospinal irradiation (23.4 Gy) and with posterior fossa boost (55.8 Gy), and vincristine was administered weekly during radiotherapy. After the completion of radiotherapy, patients were randomly assigned to groups that received either the standard regimen of lomustine, cisplatin, and vincristine or the alternative regimen of cyclophosphamide, cisplatin, and vincristine. The 5-year event-free survival for the 379 eligible patients enrolled was 81% + 2%, and there was no difference in eventfree survival in either arm of the study. 3 On the basis of this result, the current Children's Oncology Group (COG) is conducting a randomized study that is seeking to further reduce the dose of craniospinal irradiation to 18 Gy while maintaining the same degree of disease control.
Recently concluded studies from Europe have attempted to answer the question of timing of chemotherapy in relation to radiotherapy. The SIOP II study clearly demonstrated that use of prolonged preradiotherapy chemotherapy negatively affects the event-free survival estimate for average-risk patients. The negative result could also be attributed to the choice of drugs given before radiotherapy, because this chemotherapy regimen did not contain cisplatin, a drug that is particularly effective against medulloblastoma. 22 The recently concluded SIOP III study compared event-free survival estimates for patients treated with radiotherapy alone with those for patients treated with vincristine, carboplatin, cyclophosphamide, and etoposide for 4 cycles and subsequent radiotherapy. The dose of craniospinal irradiation was 36 Gy, and the dose to the posterior fossa was 56 Gy. In contrast to US studies that exclude M1 patients from average-risk protocols, patients with M0 and M1 disease were enrolled on this study; therefore, the comparison of these data with those from the United States is difficult. Of the 217 patients enrolled in the SIOP III study, 179 were eligible for analysis. The event-free survival probability at 5 years for the group that received chemotherapy and radiotherapy was 74%, whereas that for the group that received only radiotherapy was 60% (P ¼ .036). This study confirms that postoperative standard-dose craniospinal irradiation alone achieves 5-year event-free survival rates of between 60% and 65% and that this can be improved with the addition of platinum-based chemotherapy. 13 The HIT (Hirntumorprotokoll [German]) '91 trial compared the outcome of patients receiving preradiotherapy or postradiotherapy chemotherapy. A total of 280 patients were enrolled in the study. Patients with M1 disease and residual tumor following surgery were included in the average-risk group. Among the 234 average-risk patients were 69 patients with residual tumor and 49 patients with M1 disease. Once again, these disease risk criteria render any comparisons with US study data problematic. Postradiotherapy chemotherapy included 8 cycles consisting of lomustine, cisplatin, and vincristine. Radiotherapy for all patients consisted of craniospinal irradiation (35.2 Gy) and irradiation of the posterior fossa (55.2 Gy). Preradiotherapy chemotherapy included procarbazine, ifosfamide/etoposide, high-dose methotrexate, cisplatin, and cytosine arabinoside. Patients whose tumor responded poorly to the preradiotherapy chemotherapy were given additional chemotherapy consisting of carboplatin, lomustine, and vincristine after radiotherapy. The 5-year progression-free survival estimate for patients in the postradiotherapy chemotherapy arm was 78% + 6%, whereas that for patients in the preradiotherapy chemotherapy group was 65% + 5% (P ¼ .03). 14 The results for the postradiotherapy chemotherapy arm confirm those seen in US studies in which a similar approach was used, albeit with a lower dose of craniospinal irradiation and a more clearly defined group of average-risk patients.
Collectively, these studies have demonstrated that the addition of adjuvant chemotherapy has improved the cure rates for average-risk medulloblastoma. Current protocols are testing the feasibility of further reducing the dose of craniospinal irradiation.
Chemotherapy for High-Risk Patients
Attempts to improve survival estimates for high-risk patients ( 1.5 cm 2 residual disease or presence of metastatic disease) have relied on a variety of chemotherapy regimens administered before or after radiotherapy (Table 1) . Historically, high-risk patients treated with radiotherapy alone have had 5-year progression-free survival estimates of 25% to 40%. 23 In a trial conducted at 5 institutions and reported by Packer and colleagues, the 5-year progression-free survival probability was 67% + 15% for 15 patients with Mþ disease treated with radiotherapy with concurrent vincristine and adjuvant chemotherapy consisting of lomustine, cisplatin, and vincristine. 16 The effectiveness of combined modality therapy on the progression-free survival probability of high-risk patients has been confirmed recently in the POG 9031 study. Of the 224 patients enrolled, 94 had Mþ disease. Patients were randomly assigned to 2 groups that received 3 cycles of cisplatin and etoposide either before or immediately after radiotherapy. All patients subsequently received 8 cycles of cyclophosphamide and vincristine. Patients with M1 disease received 35.2 Gy craniospinal irradiation, and most patients with M2/M3 disease received 40 Gy craniospinal irradiation with a boost of 4.8 Gy to gross sites of metastatic disease. The dose of irradiation to the posterior fossa ranged from 53.2 to 54.4 Gy. The 5-year event-free survival estimate for the patients with Mþ disease was approximately 55%, a result that confirms the pilot experience of Packer and colleagues. 24 The CCG 921 study, another large randomized study that incorporated preradiotherapy and postradiotherapy arms, enrolled 203 patients with high-risk medulloblastoma. Of these, 188 patients were randomly assigned to 1 of 2 treatment groups: an experimental arm, which received 2 cycles of 8-in-1 chemotherapy preradiotherapy and then an additional 6 cycles of the same chemotherapy, or a standard arm, which received chemotherapy similar to the regimen in the study by Packer and colleagues described earlier. Patients received 36 Gy craniospinal irradiation with a further radiotherapy boost to the primary tumor site. Estimated 5-year progression-free survival for the entire cohort of patients was 54% + 5%. Patients treated with the standard regimen of lomustine, vincristine, and prednisone had a 5-year progression-free survival probability of 63% + 5%. This estimate is similar to those noted from the Packer study and the POG study, and superior to those achieved with the investigational 8-in-1 regimen. 25 For high-risk patients, the use of preradiotherapy chemotherapy for a prolonged period of time yielded results that were clearly inferior to those obtained with the use of a shorter window (approximately 6-8 weeks of chemotherapy). Results from the Primitive Neuroectodermal Tumor (PNET) III trial and the HIT '91 trial that used preradiation chemotherapy did not demonstrate a survival advantage for patients despite the use of drugs that were active against medulloblastoma. The event-free survival for M2-M3 patients was 34.7% (n ¼ 68) at 5 years and 30% (n ¼ 19) at 3 years for the PNET III and HIT '91 trials, respectively. 14, 15 The best result for high-risk medulloblastoma to date has been published by a consortium of investigators led by St Jude Children's Research Hospital. Following maximal surgical resection of the tumor, therapy consisted of craniospinal irradiation (36 Gy M0-M1; 39.6 Gy M2-M3) with an additional radiotherapy boost to the primary tumor bed and a 2-cm margin delivered by 3-dimensional conformal technique. Six weeks after completion of radiotherapy, these investigators used 4 courses of cyclophosphamide-based dose-intensive chemotherapy, with hematopoietic stem cell support, over 16 weeks. The 5-year event-free survival for 48 patients with high-risk medulloblastoma was 70% at 5 years. 2 This study suggests that chemotherapy does significantly improve the survival for patients with high-risk medulloblastoma, but the sequencing of chemotherapy is crucial to achieve good results. Despite using drugs with proven efficacy against medulloblastoma, neoadjuvant chemotherapy used for a duration of greater than 6 weeks may have a detrimental impact on event-free survival in high-risk patients.
Genome-wide analysis using microarray technology has contributed significantly to our understanding of medulloblastoma biology. 26, 27 It is now apparent that medulloblastoma is not a single disease entity but actually consists of tumors that arise because of distinct underlying molecular aberrations and that have different pathological morphology that affects prognosis. 28 Future trials will seek to leverage this knowledge to design molecular and clinical risk-adapted trials that combine standard chemotherapy drugs and more novel molecularly targeted therapies. 29, 30 
High-Grade Gliomas
This histologically diverse group of tumors consists of anaplastic astrocytoma (World Health Organization grade 3), glioblastoma multiforme (World Health Organization grade 4), and, less commonly, high-grade oligodendroglial or mixed astrocytic tumors (World Health Organization grade 3). High-grade gliomas comprise approximately 8% to 12% of all childhood central nervous system tumors and most often originate from the supratentorial area, but rarely they can also originate from the cerebellum. Their incidence in childhood peaks among older adolescents; however, they do occur rarely in young children. In spite of modern aggressive multimodality therapy including surgery, radiotherapy, and chemotherapy, survival remains dismal. 8 Outcome is worse for children with glioblastoma than for those with anaplastic astrocytoma. 31 The best outcomes are obtained for children with high-grade oligodendroglial or mixed astrocytic tumors. 31 Maximum safe surgical resection and radiotherapy form the backbone of therapy for pediatric high-grade glioma. In contrast, the role of chemotherapy for the treatment of these neoplasms remains undefined. Despite decades of intensive investigation, no single chemotherapeutic regimen stands out as particularly beneficial and no standard chemotherapy is available for children with high-grade glioma. 8 The CCG 943 trial, after initial surgery, randomly assigned patients with high-grade astrocytoma to receive local radiotherapy alone or radiotherapy with weekly vincristine, followed by 1 year of prednisone, lomustine, and vincristine. 32 A total of 58 patients was enrolled in this study (40 patients with glioblastoma multiforme and 18 with anaplastic astrocytoma). Patients treated with radiotherapy alone had a 5-year progression-free survival rate of 18% compared with 46% for those who received radiotherapy and chemotherapy. Notably, this study demonstrated a statistically significant improved outcome for patients with glioblastoma multiforme treated with chemotherapy: estimated 5-year progression-free survival was 42% compared with 6% for those treated with radiotherapy alone. However, these results have never been reproduced in other studies, raising concerns about the histologic diagnosis of these patients.
The subsequent CCG study, CCG 945, compared radiotherapy and procarbazine, lomustine, and vincristine chemotherapy (CCG 943 therapy-standard arm) to a combination of local radiotherapy and 8-in-1 chemotherapy administered preradiotherapy and postradiotherapy. 31 The study enrolled 172 newly diagnosed children with high-grade glioma who had undergone surgical resection. There was no statistical difference in 5-year progressionfree survival between patients receiving standard therapy and the group receiving the 8-in-1 regimen (26% compared with 33%; (P > .52). The 5-year progression-free survival rate was 28% + 7% for patients with anaplastic astrocytoma and 16% + 7% for patients with glioblastoma multiforme. A follow-up retrospective analysis by a panel of expert neuropathologists of 169 of 172 tumor samples in the above study revealed that 30% of the patients enrolled in this study did not harbor high-grade gliomas. When tumors were classified according to institutional and consensus panel criteria, the 5-year survival estimates dropped from 36% + 5% (standard) and 40% + 5% (8-in-1) to 19% + 5% (standard) and 23% + 5% (8-in-1), demonstrating the importance of central pathologic review. 33 German investigators, on the other hand, tested the efficacy of alternative cytotoxic agents applied preradiotherapy, termed sandwich chemotherapy. Patients were randomly assigned after surgery to receive alternating cycles of ifosfamide/etoposide, high-dose methotrexate, and cisplatin/cytarabine for 17 weeks, followed by radiotherapy or radiotherapy along with vincristine followed by 8 cycles of vincristine, lomustine, and cisplatin. 34 Poor patient accrual resulted in early closure of the study and the study randomized a total of 52 children with nonbrain stem high-grade glioma. Although the event-free survival in both groups was similar, patients receiving sandwich chemotherapy who underwent more radical resections had a statistically better survival compared with a similar group receiving maintenance chemotherapy. 34 For adults with newly diagnosed glioblastoma multiforme, temozolomide is considered the standard chemotherapy. 35 The standard of care for adult patients with glioblastoma multiforme consists of radiation therapy followed by 6 months of temozolomide. 36 The DNA repair gene, O 6 -methylguanine-DNA-methyltransferase (MGMT), removes methylated adducts from the O 6 -guanine position, which represents the principal mechanism of resistance to temozolomide. In adults, epigenetic silencing of MGMT by promoter methylation has been associated with improved outcome for patients with glioblastoma multiforme receiving temozolomide. 36, 37 However, whether such a correlation exists for children with high-grade glioma remains to be determined.
A multi-institutional study coordinated by St Jude Children's Research Hospital (St Jude High Grade (SJHG)-98) between 1999 and 2002 tested the efficacy of temozolomide in patients with non-brain stem high-grade glioma (48% glioblastoma multiforme, 32% anaplastic astrocytoma). After surgery, patients received radiotherapy and 6 cycles of temozolomide. 38 The study also included an optional window therapy of irinotecan. A total of 31 eligible patients were enrolled. The 1-and 2-year progressionfree survival estimates in this study were 43% + 9% and 11% + 5%, respectively. The 1-and 2-year overall survival estimates were 63% + 8% and 21% + 7%, respectively. 38 Patients with anaplastic astrocytoma fared significantly better than those with glioblastoma multiforme; 2-year progressionfree survival estimate was 0 for 15 patients with glioblastoma multiforme compared with 20% + 10% for patients with anaplastic astrocytoma. The median time to progression after the start of radiotherapy was 0.8 years (range 0.2-1.9 years). 38 The marked differences in response to temozolomide between adults and children with highgrade glioma highlight the distinct underlying biology between these groups and support the development of therapeutic strategies based on tumor biology rather than similarities in histologic appearance.
An extensive body of knowledge regarding genetic and molecular abnormalities found in adult high-grade gliomas now exists. 39 In contrast, information about alterations present in pediatric high-grade glioma is more limited. This knowledge, coupled with a failure of current treatments, has led to the development of a variety of novel therapies that have more specific activity against tumor cells than standard cytotoxic agents. 40 The most promising of these agents for high-grade gliomas include molecularly targeted agents such as the small molecule tyrosine kinase inhibitors 41 and treatments directed against the tumor vasculature, known as antiangiogenic agents. 42 These advances hold great promise to improve future therapy.
Encouraging results have recently been reported from an adult phase 2 trial for patients with recurrent highgrade glioma using the antiangiogenic agent bevacizumab, a humanized immunoglobulin monoclonal antibody that binds to and inhibits activity of vascular endothelial growth factor in combination with irinotecan (CPT-11), 43 a topoisomerase I inhibitor. In the study reported by Vredenburgh and colleagues, 43 6-month progression-free survival and overall survival were 46% (95% confidence interval, 32%-66%) and 77% (95% confidence interval, 64%-92%) respectively, which compares favorably with historical controls. The median progression-free survival of 35 glioblastoma multiforme patients was 24 weeks (95% confidence interval, 18-36 weeks) and overall survival was 42 weeks (95% confidence interval, 35-60 weeks).
Twenty of 35 patients had at least a partial response. Seven have completed a full year of therapy and 6 of the 7 had a cold positron emission tomography scan, suggesting no residual high-grade tumor. 43 The Pediatric Brain Tumor Consortium (PBTC) is conducting a phase 2 trial (PBTC-022) using a combination of bevacizumab plus irinotecan in children with recurrent, progressive, or refractory malignant gliomas and diffuse/intrinsic brain stem gliomas to determine whether the adult data can be replicated in pediatric patients.
Diffuse Pontine Glioma
The vast majority of pontine gliomas (85%-90%) are diffuse infiltrative, malignant (anaplastic astrocytoma/ glioblastoma multiforme) intrinsic tumors that are not amenable to resection. The diagnosis is based on typical MRI appearance, and a biopsy is not indicated. Despite numerous trials, survival has not changed for decades; the median survival after diagnosis remains less than 1 year and long-term overall survival is still less than 10%. 44 Radiotherapy forms the cornerstone of treatment but is not curative. It produces responses in many patients, but for the vast majority, tumor progression usually occurs within 5 to 10 months from the beginning of radiotherapy. No chemotherapeutic agent or regimen, 44 including myeloablative regimens with autologous stem cell rescue, 45 has influenced survival. Multi-institutional trials using highdose hyperfractionated X-ray therapy have also failed to prolong survival. 46 These dismal outcomes have prompted investigators to study various molecularly targeted and/or antiangiogenic therapies in combination with radiotherapy.
Brain Tumors in Very Young Children
The realization in the 1980s that craniospinal irradiation results in devastating consequences on the developing central nervous system of very young children prompted investigators to devise strategies to avoid or delay craniospinal irradiation for this group of children. During the 1990s, several studies were conducted to address this issue ( Table 2 ). The POG and the CCG adopted a delayed radiotherapy approach (POG 8633/34 [termed Baby POG-1] 47,48 and CCG 921 trials 54 ). In Baby POG-1, children under the age of 3 years were treated with chemotherapy consisting of vincristine, cyclophosphamide, etoposide, and cisplatin. Depending on patient age, craniospinal irradiation was delivered at 1 or 2 years after diagnosis. Using this approach, craniospinal irradiation was successfully delayed in only 40% of patients. The 5-year progression-free survival was 31.8% + 8.3% and overall survival was 39.7% + 6.9% for all medulloblastoma patients. Of note, medulloblastoma patients with nonmetastatic and gross totally resected tumor (M0R0) had much better outcomes, with 5-year overall survival of 69%. In an attempt to improve outcome, the succeeding POG study 9233/34 (termed Baby POG-2) 55 intensified the chemotherapy regimen. Patients were randomly assigned to standard Baby POG-1 treatment or an intensified version of Baby POG-1 therapy in which the same drugs were administered at higher doses and more frequently. No difference in event-free survival or overall survival was observed between patients receiving standard or intensified Baby POG therapy. 55 The CCG, which also adopted the strategy of delayed craniospinal irradiation in infants with brain tumors, conducted the CCG 921 trial 54 over the same time as the Baby POG-1 study. However, this study only included children younger than 18 months. Patients were treated with the 8-in-1 chemotherapy regimen, followed by delayed craniospinal irradiation or focal radiotherapy. Only 10% (9 of 91) of patients received the planned radiotherapy. Patients with medulloblastoma had a 3-year progression-free survival of 22%. The outcome for patients with M0R0 disease was marginally superior (5-year progression-free survival, 30%). 54 Similar to the POG study, the succeeding CCG trial (CCG 9921) also used a strategy of more intensive chemotherapy to improve outcome. Children younger than 3 years were randomly assigned to receive 1 of 2 five-cycle induction chemotherapy regimens, followed by a uniform regimen of maintenance chemotherapy for 56 weeks. Patients with residual or metastatic disease were to receive focal radiotherapy or craniospinal irradiation at the end of maintenance or at 3 years, whichever came sooner. However, like the previous CCG trial, only a minority (40%) of patients received radiotherapy as planned. There was no difference in event-free survival or overall survival between chemotherapy arms. Although outcomes were improved compared with the previous CCG trial, they were comparable to the Baby POG-1 results, with a 5-year event-free survival for all medulloblastoma patients of 32% + 5% and 5-year overall survival for completely resected M0 medulloblastoma of 54% + 8%. 49 These studies demonstrated that radiotherapy could be delayed or even omitted without compromising survival in a subset of medulloblastoma patients younger than 3 years at diagnosis.
The less than optimal survival and neurocognitive results achieved using delayed craniospinal irradiation prompted investigators to evaluate alternative approaches. 10 One alternative to delayed craniospinal irradiation is to only administer radiotherapy at the time of disease recurrence or progression. The French Baby Brain French Society of Pediatric Oncology (BBSFOP) trial adopted such a strategy by treating patients younger than 4 years with only conventional chemotherapy, reserving radiotherapy (focal to the posterior fossa only) and combined high-dose chemotherapy with autologous stem cell rescue for patients with tumor progression or recurrence. 50 The BBSFOP chemotherapy regimen resulted in a 5-year progressionfree survival of 29% (95% confidence interval, 18%-44%) for M0R0 patients, revealing that this subset can achieve long-term survival with no radiotherapy and relatively mild chemotherapy. Many patients were successfully salvaged with radiotherapy (either craniospinal irradiation or focal radiotherapy, depending on the extent of disease) and high-dose chemotherapy with autologous stem cell rescue, resulting in a 5-year overall survival for M0R0 patients of 73% (95% confidence interval, 59%-84%). 50 To avoid craniospinal irradiation, German investigators used a strategy of high-dose systemic and intensive intraventricular methotrexate combined with standard chemotherapy. 51 Using this approach, the HIT-SKK92 14) were also somewhat better than in prior series, with 5-year progression-free survival of 50% + 13% and overall survival of 56% + 14%. Only patients with macroscopic metastasis (M2-M3; n ¼ 12) fared poorly, with 5-year progression-free survival of 33% + 14% and overall survival of 38% + 15%. This study reported no toxic deaths, but there was a very high frequency (19 of 23 [83%] evaluated patients) of asymptomatic leukoencephalopathy noted on MRI, most likely attributable to the intensive use of intrathecal methotrexate. Additionally, the mean IQ of survivors, although higher than historical controls that received whole-brain radiotherapy, was significantly lower than that of age-matched controls. 51 This study revealed that the majority of young children without macroscopic metastasis and completely resected medulloblastoma can be cured with chemotherapy alone, but at a cost of methotrexate-induced neurotoxicity. The use of myeloablative chemotherapy with autologous stem cell rescue has also been investigated as an alternative to craniospinal irradiation. This approach was used by the Head Start II trial, which used 5 cycles of induction chemotherapy very similar to regimen A of CCG 9921, but with the addition of high-dose intravenous methotrexate, followed by a single consolidation course of myeloablative therapy using carboplatin, thiotepa, and etoposide with autologous stem cell rescue. Using this strategy, the Head Start II trial has achieved the best results to date for young children (defined as age < 6 years in this trial) with metastatic medulloblastoma (M1-M3; n ¼ 21), with 3-year event-free survival of 49% (95% confidence interval, 27%-72%) and overall survival of 60% (95% confidence interval, 36%-84%), respectively. 53 Although promising, interpretation of these results is limited by the small size of the study and inclusion of older children (only 9 patients under age 3 years at diagnosis were enrolled). 53 Children less than 3 years with M0 medulloblastoma treated on Head Start I and II trials were treated with identical therapy as patients with metastatic disease, except they did not receive high-dose methotrexate. For patients with M0R0 medulloblastoma (n ¼ 14), the results of this trial are comparable with those of the German group, with 5-year event-free survival of 64% + 13% and overall survival of 79% + 11%. 52 However, these results were achieved with a high toxic death rate (19%) from treatment-related complications. 52 This strategy appears to add no benefit for patients with nonmetastatic residual disease (M0R1; n ¼ 7), as the 5-year event-free survival of 29% + 17% for this group 52 is comparable to the CCG 9921 trial result of 26% + 9%, 49 which was achieved without the use of myeloablative chemotherapy with autologous stem cell rescue.
On the basis of the Head Start regimen, the CCG tested the feasibility of delivering multiple courses of myeloablative chemotherapy with autologous stem cell rescue (termed tandem transplants) as part of the CCG 99703 trial (n ¼ 21). Patients younger than 3 years received 3 cycles of intensive standard chemotherapy followed by 3 cycles of myeloablative chemotherapy with autologous stem cell rescue. Results are pending.
Recent improvements in radiotherapy delivery techniques, permitting more precise tumor targeting, have generated renewed interest in the use of focal radiotherapy for very young patients with localized disease. This strategy has been implemented in 2 recent trials: the COG P9934 study and the PBTC-001 study. The COG P9934 included focal radiotherapy after 16 weeks of induction chemotherapy for patients with M0R0 medulloblastoma. In the PBTC-001 study, patients received standard chemotherapy plus intrathecal mafosfamide for 20 weeks, followed by focal radiotherapy, and then 20 weeks of maintenance chemotherapy. Results from these trials are pending.
Atypical teratoid/rhabdoid tumor has only recently been recognized as a distinct tumor entity from other central nervous system embryonal tumors. 56, 57 Atypical teratoid/rhabdoid tumor is highly aggressive and occurs primarily in children younger than 2 years, who frequently present with metastatic disease at diagnosis. In the past, many patients with atypical teratoid/rhabdoid tumor were probably classified with medulloblastoma or PNET. Thus, the classification of atypical teratoid/rhabdoid tumor as a distinct entity may also account for some of the improvement in outcome for young children with medulloblastoma and PNETs. Atypical teratoid/rhabdoid tumors are characterized by alterations in the SMARCB1 (also known as INI1/hSNF5/) gene on chromosome 22q11. The majority (85%) of atypical teratoid/rhabdoid tumors have inactivation of SMARCB1, either through homozygous deletions or loss of one allele with concomitant mutation of the other copy. Older children with atypical teratoid/ rhabdoid tumors have been successfully treated with a combination of complete resection, craniospinal irradiation, and high-dose chemotherapy with autologous stem cell rescue. 58 In contrast, possibly because of the omission of craniospinal irradiation, outcomes for children younger than 3 years of age are dismal. 49, 58 The 2-year event-free survival for 28 children less than 3 years old treated on the CCG 9921 trial was 14% + 7%. 49 Likewise, in the St Jude experience reported by Tekautz and colleagues, the 2-year event-free survival for the 22 children less than 3 years at diagnosis was 11% + 6%. 58 Effective chemotherapy regimens for young children with atypical teratoid/rhabdoid tumors remain elusive.
Conclusion
Although surgery and radiotherapy are the mainstay of therapy for older children with medulloblastoma, chemotherapy has also played a key role. Medulloblastoma is the first brain tumor to show efficacy of chemotherapy in large prospective trials. On the other hand, many children with brain tumors remain incurable with current therapies. Effective chemotherapy regimens remain elusive for almost all patients with high-grade cortical or brain stem gliomas and for most young patients with residual or metastatic disease of any histology. In the past 3 decades, chemotherapeutic agents have been extensively evaluated for the treatment of brain tumors in a myriad of schedules, doses, and combinations. A plateau in efficacy has been reached. Further treatment intensification using conventional nonspecific chemotherapy is more likely to result in additional toxicity without major advances in survival. Modest improvements in outcome may be achieved by further refining treatment schedules, introducing new chemotherapeutic agents.
Novel approaches to chemotherapy administration and delivery such as continuous low-dose administration of chemotherapy, known as metronomic chemotherapy, have been shown to have antiangiogenic properties and have demonstrated objective response rates in pediatric patients. 59 Additionally, convection-enhanced delivery of immunotoxin conjugates is being explored as potential therapy for pediatric cortical high-grade gliomas.
Although conventional chemotherapeutic agents continue to be developed to reduce toxicity and/or improve efficacy, the remarkable advances made in knowledge of tumor biology in the past decade have shifted the focus onto novel agents that target molecular changes crucial for tumor proliferation or survival. These selective agents are predicted to be less toxic to normal cells and it is anticipated that they will be more effective than currently used nonspecific chemotherapeutic agents. The toxicity and efficacy of several of these novel agents is currently being assessed in children with brain tumors. Ultimately, if these novel therapies prove effective, their role in combination with established chemotherapeutic agents will need to be assessed.
